We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.21%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$290M
AUM Growth
+$16.2M
Cap. Flow
-$4.34M
Cap. Flow %
-1.5%
Top 10 Hldgs %
25.51%
Holding
174
New
37
Increased
46
Reduced
48
Closed
32

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$3.3M
2
GEV icon
GE Vernova
GEV
+$2.82M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$2.76M
4
DYN icon
Dyne Therapeutics
DYN
+$2.61M
5
AMZN icon
Amazon
AMZN
+$2.59M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$6M
2
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$4.02M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$3.97M
4
MRUS
Merus
MRUS
+$2.23M
5
META icon
Meta Platforms (Facebook)
META
+$2.06M

Sector Composition

Rank Sector Weight
1 Healthcare 46.45%
2 Technology 15.69%
3 Consumer Discretionary 9.1%
4 Industrials 4.98%
5 Financials 4.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBC icon
1
Invesco DB Commodity Index Tracking Fund
DBC
$1.69B
$32M 11.03%
1,436,136
– –
AMZN icon
2
Amazon
AMZN
$2.44T
$6M 2.07%
32,193
+14,200
+79% +$2.59M
PCVX icon
3
Vaxcyte
PCVX
$7.65B
$5.1M 1.76%
44,661
+12,348
+38% +$1.11M
ACLX
4
DELISTED
Arcellx
ACLX
$4.6M 1.59%
55,139
+4,099
+8% +$273K
CTLT
5
DELISTED
CATALENT, INC.
CTLT
$4.58M 1.58%
75,600
– –
CRM icon
6
Salesforce
CRM
$154B
$4.54M 1.57%
16,585
-4,600
-22% -$1.18M
JNPR
7
DELISTED
Juniper Networks
JNPR
$4.47M 1.54%
114,700
– –
HCP
8
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
$4.41M 1.52%
130,200
– –
VRDN icon
9
Viridian Therapeutics
VRDN
$2.2B
$4.21M 1.45%
185,240
-13,244
-7% -$217K
ANSS
10
DELISTED
Ansys
ANSS
$4.08M 1.41%
12,800
– –
XPO icon
11
XPO
XPO
$23.4B
$4.05M 1.4%
37,680
+12,200
+48% +$1.37M
PTGX icon
12
Protagonist Therapeutics
PTGX
$8.55B
$4.03M 1.39%
89,508
+68,279
+322% +$2.76M
HES
13
DELISTED
Hess
HES
$3.92M 1.35%
28,900
– –
ARGX icon
14
argenx
ARGX
$55.2B
$3.88M 1.34%
7,154
+550
+8% +$278K
AMED
15
DELISTED
Amedisys
AMED
$3.79M 1.31%
39,250
– –
GEV icon
16
GE Vernova
GEV
$240B
$3.75M 1.29%
+14,700
New +$2.82M
AXSM icon
17
Axsome Therapeutics
AXSM
$11.7B
$3.73M 1.29%
41,542
-20,650
-33% -$1.8M
MRUS
18
DELISTED
Merus
MRUS
$3.7M 1.27%
73,980
-42,738
-37% -$2.23M
APGE icon
19
Apogee Therapeutics
APGE
$10.1B
$3.63M 1.25%
61,788
-17,154
-22% -$822K
ACI icon
20
Albertsons Companies
ACI
$5.85B
$3.49M 1.2%
188,753
– –
INSM icon
21
Insmed
INSM
$22.4B
$3.32M 1.14%
45,447
-81,333
-64% -$6M
CPRI icon
22
Capri Holdings
CPRI
$1.82B
$3.3M 1.14%
77,700
– –
AMGN icon
23
Amgen
AMGN
$209B
$3.25M 1.12%
+10,101
New +$3.3M
CART icon
24
Maplebear
CART
$10.7B
$3.2M 1.1%
78,500
-14,488
-16% -$509K
BCYC
25
Bicycle Therapeutics
BCYC
$269M
$3.16M 1.09%
139,544
+12,289
+10% +$283K
1
2 3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return

HighVista Strategies's Q3 2024 Portfolio in Review

As of Q3 2024, HighVista Strategies held 174 positions worth $290M, up 5.9% from $274M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

HighVista Strategies's Q3 2024 filing shows 37 new, 46 increased, 48 reduced and 32 closed positions. Its largest new stake was Amgen: 10,101 shares worth $3.25M. The largest sale was Insmed, an estimated $6M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 44% a quarter earlier, followed by Technology and Consumer Discretionary.

  • HighVista Strategies's largest Q3 2024 buy was Amgen: 10,101 shares worth $3.25M.
  • HighVista Strategies added most to Protagonist Therapeutics in Q3 2024, an estimated $2.76M increase.
  • HighVista Strategies's biggest Q3 2024 reduction was Insmed, cutting an estimated $6M.
  • HighVista Strategies fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $4.02M.
  • HighVista Strategies's ten largest holdings make up 26% of its $290M portfolio in Q3 2024.
  • HighVista Strategies opened 37 new positions and closed 32 in Q3 2024.
  • HighVista Strategies's portfolio value rose 5.9% quarter-over-quarter to $290M.

Based on HighVista Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.